论文部分内容阅读
对144名处于HBV感染高危状态的医务人员(18～62岁,平均33岁)接种了血源乙型肝炎疫苗(20μg),免疫程序为第0、1和6个月接种疫苗,每次接种前及接种后第9个月采血检测抗-HBs。并对接种者随访2年。作者认为,抗-HBs水平≥5～10IU/1时,对HBV有防御作用,而在第9个月时,抗-HBs水平应达50IU/1以上。免疫后9个月,82.6%(119/144)的人抗-HBs水平≥50IU/1;9%(13/144)的人抗-HBs<50IU/1;8.3%(12/144)的人无应答。对8例低应答者在第9个月时给予第4针免
Blood-borne hepatitis B vaccine (20 μg) was administered to 144 medical staff (aged 18-62 years, mean age 33 years) at a high risk of HBV infection and immunized at 0, 1 and 6 months of vaccination. Each vaccination Anti-HBs were tested before and at the 9th month after inoculation. And the follow-up of vaccination 2 years. The authors believe that anti-HBs levels of 5 ~ 10IU / 1, on the defensive effect of HBV, and in the first 9 months, anti-HBs level should reach 50IU / 1 above. At 9 months post immunization, 82.6% (119/144) of human anti-HBs levels were> 50 IU / 1; 9% (13/144) of human anti-HBs <50 IU / 1; 8.3% (12/144) No answer. Eight patients with low responders at the 9th month to give the fourth needle free